- Home
- IONS vs MDGL Comparison
IONS vs MDGL Comparison
Compare IONS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- MDGL
- Stock Information
- Founded
- IONS 1989
- MDGL 2011
- Country
- IONS United States
- MDGL United States
- Employees
- IONS N/A
- MDGL N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- IONS Health Care
- MDGL Health Care
- Exchange
- IONS Nasdaq
- MDGL Nasdaq
- Market Cap
- IONS 6.8B
- MDGL 6.1B
- IPO Year
- IONS 1991
- MDGL N/A
- Fundamental
- Price
- IONS $42.25
- MDGL $298.40
- Analyst Decision
- IONS Buy
- MDGL Strong Buy
- Analyst Count
- IONS 15
- MDGL 9
- Target Price
- IONS $57.13
- MDGL $420.63
- AVG Volume (30 Days)
- IONS 1.8M
- MDGL 360.9K
- Earning Date
- IONS 07-30-2025
- MDGL 08-05-2025
- Dividend Yield
- IONS N/A
- MDGL N/A
- EPS Growth
- IONS N/A
- MDGL N/A
- EPS
- IONS N/A
- MDGL N/A
- Revenue
- IONS $717,253,000.00
- MDGL $317,383,000.00
- Revenue This Year
- IONS $9.08
- MDGL $286.17
- Revenue Next Year
- IONS $14.72
- MDGL $64.17
- P/E Ratio
- IONS N/A
- MDGL N/A
- Revenue Growth
- IONS N/A
- MDGL N/A
- 52 Week Low
- IONS $23.95
- MDGL $200.63
- 52 Week High
- IONS $52.34
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- IONS 60.76
- MDGL 45.49
- Support Level
- IONS $41.25
- MDGL $307.43
- Resistance Level
- IONS $42.81
- MDGL $357.91
- Average True Range (ATR)
- IONS 1.18
- MDGL 14.09
- MACD
- IONS -0.27
- MDGL -2.88
- Stochastic Oscillator
- IONS 42.36
- MDGL 18.38
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.